Explo-Lab near Flamboro ON (2025 Result(s))

Dr. James Watt works with his team of x-ray and ultrasound technologists, and receptionists to ensure referring doctors receive accurate reports in an efficient and professional manner.

We are ONE STOP Quality and Compliant service solution located in Mississauga,ON,Canada for pharmaceutical, nutraceutical, cosmetic, medical device, food and water.One can find Fresh look of Our Prowess in analytical and consultancy services. We offer different services such as Raw materials and Finished product testing, Elemental analysis (ICP-MS), In-Vitro Analysis( USING FRANZ CELL),Dissolution testing(USP apparatus 1,2,3,4),Compendial and standardized testing (USP,EP,and others), Formulation development support, Deformulation studies, Analytical method Development, Analytical Method Validation, GMP audit, Quality Assurance and Regulatory Affairs services(Drug product submission and Registration in Canada, USA, Europe and emerging market

Why a Shaw Group LabEach of the Shaw Group lab managers is available as your personal consultant on all matters related to case planning, technical discussions, and your laboratory requirements. Our lab managers and technicians continue their path to maintain a contemporary professional level with on-going attendance at continuing education seminars and technical courses to further expand their high level of knowledge and expertise.Whether you should require information on implants, bonding techniques, materials, or the latest advancements in our industry, don't hesitate to contact a Shaw Group 'Centre of Excellence' dental lab. Our goal at the Shaw Group of Dental Laboratories is to continue to offer an excellent choice of complete dental laboratory services, just as we have over the past 70 years.We welcome new clients and look forward to the opportunity of becoming an integral part of your cosmetic dental team!

Often, pharmaceutical companies avoid new laboratory testing methodologies preferring to stick to established procedures for drug development so as to avoid any potential regulatory ambiguity. This tendency to avoid new methodologies and regulatory scrutiny sometimes leads to slower progress, higher costs and lower probability of new product approvals. Furthermore, some pharmaceutical firms severely restrict academic research-based modifications to established laboratory testing procedures in drug development because of their concern over triggering costly adjustments to the established regulatory framework.

Viventia is developing and advancing the next generation of human antibody-based therapeutics for use in oncology. Our approach combines the specificity of an antibody with the potency of a cytotoxic payload to provide targeted therapies for the safer and more efficacious treatment of cancer patients. Viventia has developed a potent payload, deBouganin, that when coupled to a targeting antibody can effectively kill cancer cells without harming normal cells. This differential targeting enhances the therapeutic potential of our drugs and provides prolonged clinical benefit. The versatile deBouganin payload has been chemically conjugated to full length antibodies as well as fused to numerous antibody fragments and has been found to be safe and efficacious in the clinic.